Spectral Medical Provides Tigris Trial Update - BioSpace
Spectral Medical Inc. updates on Tigris trial, a Phase 3 study for Polymyxin B Hemoperfusion in treating endotoxemia and septic shock, with 101 patients enrolled. Aiming for full enrollment, the company hosted an Investigator Meeting to support trial sites. PMX, Spectral's therapeutic device, targets septic shock treatment, with FDA Breakthrough Device Designation.
Reference News
Spectral Medical Inc. updates on Tigris trial, a Phase 3 study for Polymyxin B Hemoperfusion in treating endotoxemia and septic shock, with 101 patients enrolled. Aiming for full enrollment, the company hosted an Investigator Meeting to support trial sites. PMX, Spectral's therapeutic device, targets septic shock treatment, with FDA Breakthrough Device Designation.
Spectral Medical reported a 54% revenue increase to $471,000 in Q2, focusing on its Tigris trial for Toraymyxin, a septic shock treatment. With $7.5m in cash reserves and a partnership with Baxter for post-approval marketing, Spectral aims to complete the trial by late 2024, targeting FDA approval for PMX.